This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


GlaxoSmithKline plc

Drug Names(s): iodine131-labeled B-lymphocyte stimulator, LR131

Description: LymphoRad is a radioiodinated form of BLyS, the B cell stimulating protein discovered by and being developed by HGSI. Preclinical data demonstrate that the construct binds to receptors found only on the surfaces of B cells and B cell tumors, delivering low doses of radiation causing cell death.

Deal Structure: In July 2012, GlaxoSmithKline and Human Genome Sciences entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash. The acquisition was completed in August 2012.

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug